BeyondSpring Inc. (BYSI) Stock Score, Valuation & Financial Research

BeyondSpring Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BYSI

BeyondSpring Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.77. These figures are a research snapshot, not a buy or sell recommendation.

What BeyondSpring Inc. does

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

BeyondSpring is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity and debt financing to fund the research, development, and clinical trials of its proprietary drug candidates, primarily Plinabulin, with the goal of eventually commercializing these therapies.

Products and services

  • The company's primary product candidate is Plinabulin, a small-molecule agent in late-stage clinical development designed as an anti-cancer agent and immune modulator for various indications, including non-small cell lung cancer (NSCLC).

Brands and product families

  • Plinabulin — Lead clinical-stage drug candidate for cancer treatment. Source

Customer types

Clinical trial sites and patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturers for the production of its drug candidates for clinical trials; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various established pharmaceutical and biotechnology firms developing oncology therapies and immune modulators. Source

Business strengths to evaluate

  • Proprietary Plinabulin platform with novel mechanism of action Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BYSI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.77
Market capitalization:
31.66M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -6.69M
Free cash flow:
USD -20.07M
Cash:
USD 2.7M
Total debt:
USD 171K
EPS:
USD -0.17

What stands out

  • Free cash flow is USD -20.07M, negative for the stored period.
  • The balance sheet shows USD 2.7M of cash versus USD 171K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.53M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BYSI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BYSI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BYSI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BYSI to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of BYSI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research BYSI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.